Azor

Azor Bio is a preclinical-stage biotechnology company developing a proprietary Microbiome-Triggered Drug Delivery (MTDD) platform. The company's technology utilizes azo-bond chemistry to create prodrugs that remain stable during transit through the upper gastrointestinal tract and are specifically cleaved by azoreductase enzymes produced by the colonic microbiota. This site-specific activation allows for the targeted release of therapeutic payloads directly in the colon, maximizing local drug concentration while minimizing systemic exposure and associated side effects. Azor Bio is primarily targeting gastrointestinal disorders, including ulcerative colitis and Crohn's disease, by optimizing the delivery of both established and novel therapeutic agents.